Literature DB >> 18186707

The challenge of hepatitis C in the HIV-infected person.

David L Thomas1.   

Abstract

Hepatitis C virus (HCV) coinfection occurs in an estimated one quarter of HIV-infected persons in Europe, Australia, and the United States. As use of highly active antiretroviral drugs has markedly reduced opportunistic infections, HCV-related liver disease has emerged as a leading cause of death. HIV infection adversely affects both the natural history and the treatment of hepatitis C. Because there are no experimental models of coinfection and because the pathogenesis of each infection is incompletely understood, how HIV infection alters hepatitis C is not clear. This review considers the epidemiology, natural history, treatment, and pathogenesis of hepatitis C in HIV-infected persons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18186707     DOI: 10.1146/annurev.med.59.081906.081110

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  37 in total

1.  Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Authors:  Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

2.  Hepatocellular carcinoma in patients co-infected with hepatitis C virus and human immunodeficiency virus.

Authors:  Dimitrios Dimitroulis; Serena Valsami; Eleftherios Spartalis; Emmanuel Pikoulis; Gregory Kouraklis
Journal:  World J Hepatol       Date:  2013-06-27

3.  [Not Available].

Authors:  Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

Review 4.  Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus coinfection with special reference to hemophiliac recipients in Japan.

Authors:  Susumu Eguchi; Akihiko Soyama; Masaaki Hidaka; Mitsuhisa Takatsuki; Izumi Muraoka; Tetsuo Tomonaga; Takashi Kanematsu
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

Review 5.  Pathogen-pathogen interaction: a syndemic model of complex biosocial processes in disease.

Authors:  Merrill Singer
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

6.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

Authors:  Mark Hull; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Giguère; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

7.  Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.

Authors:  Long Zhang; David D Celentano; Nguyen Le Minh; Carl A Latkin; Shruti H Mehta; Constantine Frangakis; Tran Viet Ha; Tran Thi Mo; Teerada Sripaipan; Wendy W Davis; Vu Minh Quan; Vivian F Go
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-05       Impact factor: 2.566

8.  Optimizing hepatitis C therapy in HIV/hepatitis C virus (HCV) coinfected patients: Analysis of HCV viral kinetics on treatment.

Authors:  Paul Damien James; David Kh Wong
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

9.  Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfection.

Authors:  Alexander J Millman; Qingwei Luo; Noele P Nelson; Claudia Vellozzi; John Weiser
Journal:  AIDS Care       Date:  2019-09-23

10.  High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China.

Authors:  Hong Shang; Ping Zhong; Jing Liu; Xiaoxu Han; Di Dai; Min Zhang; Ke Zhao; Rongzhen Xu; Xiao-Fang Yu
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.